Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Origins and treatment of airway inflammation in childhood asthma
Autore:
Lemanske, RF;
Indirizzi:
Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI USA Univ Wisconsin Madison WI USA sin, Sch Med, Dept Pediat, Madison, WI USA Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA Univ Wisconsin MadisonWI USA consin, Sch Med, Dept Med, Madison, WI USA
Titolo Testata:
PEDIATRIC PULMONOLOGY
, , anno: 2001, supplemento:, 21
pagine: 17 - 25
SICI:
8755-6863(2001):<17:OATOAI>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
RESPIRATORY SYNCYTIAL VIRUS; EARLY-LIFE; YOUNG-CHILDREN; FETAL GROWTH; RISK-FACTORS; IFN-GAMMA; WHEEZE; ATOPY; TRACT; BRONCHIOLITIS;
Keywords:
asthma; respiratory syncytial virus; leukotriene receptor antagonists;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Lemanske, RF Univ Wisconsin Hosp & Clin, 600 Highland Ave,Room K4-916, Madison, WI 53792 USA Univ Wisconsin Hosp & Clin 600 Highland Ave,Room K4-916 Madison WI USA 53792
Citazione:
R.F. Lemanske, "Origins and treatment of airway inflammation in childhood asthma", PEDIAT PULM, 2001, pp. 17-25

Abstract

Several early events and risk factors are associated with the development of childhood asthma. Two significant risk factors are viral lower respiratory tract infections and atopy. Studies suggest that imbalances in T(H)1/T(H)2 cytokine responses in relationship to viral infections may play a role in the development of the childhood asthmatic phenotype, Airway inflammationis now recognized to contribute to the inception, persistence, and severity of asthmatic symptoms. The majority of information pertaining to airway inflammation in asthma has been derived from adult studies, but recent evaluations have been done in children. Available data are inconclusive as to the right medication to be used at the inception and during the evolution of the asthmatic phenotype in children. Inhaled corticosteroids (ICS) are not consistently effective in young children for a variety of reasons, including underlying pathophysiologic mechanisms that are unresponsive to the pharmacologic properties of ICS. The leukotriene receptor antagonists (LTRAs), recently approved for children as young as 2 years of age, address the relationship between leukotriene production and airway inflammation or remodeling in asthma. Therapeutic trials using LTRAs in children should prove beneficial. (C) 2001 Wiley-Liss. Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 09:15:31